Upacicalcet治疗血液透析患者继发性甲状旁腺功能亢进:随机安慰剂对照试验
这项3期双盲安慰剂对照研究纳入日本血液透析伴继发性甲状旁腺功能亢进患者,随机接受Upacicalcet或安慰剂治疗24周。Upacicalcet组67%达到目标iPTH 60-240 pg/ml,安慰剂组8%,差异59%(95%CI 48%-71%)。Upacicalcet有效且安全。
要点
- Upacicalcet组67%达到目标iPTH,安慰剂组8%,差异59%(95%CI 48%-71%)
- Upacicalcet降低FGF23、骨特异性碱性磷酸酶等骨代谢指标
- 不良事件发生率Upacicalcet组85% vs 安慰剂组72%,上消化道不良事件相似
核心结论
- Upacicalcet是一种新型可注射拟钙剂,对血液透析继发性甲状旁腺功能亢进患者有效且安全。
研究设计与样本
- 3期双盲安慰剂对照研究,纳入日本血液透析伴继发性甲状旁腺功能亢进患者,血清iPTH>240 pg/ml且校正钙≥8.4 mg/dl,随机接受Upacicalcet或安慰剂每透析后给药24周。
- Upacicalcet组103例,安慰剂组50例。
主要发现
- 主要结局:第22-24周平均血清iPTH达60-240 pg/ml的受试者比例,Upacicalcet组67%(69/103) vs 安慰剂组8%(4/50),差异59%(95%CI 48%-71%)。
- Upacicalcet降低血清FGF23、骨特异性碱性磷酸酶、总1型前胶原N端前肽、抗酒石酸酸性磷酸酶5b浓度。
- 不良事件发生率:Upacicalcet组85%(88/103) vs 安慰剂组72%(36/50);恶心呕吐等上消化道不良事件两组相似。
- 血清校正钙<7.5 mg/dl:Upacicalcet组2%,安慰剂组0%。
关键数值与推荐
- 纳入标准:血清iPTH>240 pg/ml且校正钙≥8.4 mg/dl的血液透析患者。
- 主要结局目标:第22-24周平均血清iPTH 60-240 pg/ml。
临床怎么用
- Upacicalcet每透析后给药,可有效降低iPTH并达到目标范围,同时降低骨代谢指标。
- 需关注不良事件,尤其是低钙血症(校正钙<7.5 mg/dl)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secondary hyperparathyroidism is a major complication of patients undergoing hemodialysis (HD). Upacicalcet, a new injectable calcimimetic, acts on calcium-sensing receptors to suppress parathyroid hormone (PTH) secretion. We examined the efficacy and safety of upacicalcet in patients with secondary hyperparathyroidism receiving HD. METHODS: In this phase 3, double-blind, placebo-controlled study, we randomized Japanese patients undergoing HD with serum intact PTH (iPTH) concentrations >240 pg/ml and corrected calcium concentrations ≥8.4 mg/dl. Either upacicalcet or placebo was administered after each HD session for 24 weeks. The primary outcome was the percentage of participants achieving the target mean serum iPTH concentration (60-240 pg/ml) at weeks 22-24. RESULTS: A total of 103 participants received upacicalcet, and 50 participants received the placebo. The percentage of participants achieving mean serum iPTH concentrations of 60-240 pg/ml during the evaluation period was 67% (69/103) in the upacicalcet group and 8% (4/50) in the placebo group. The difference between the two groups was 59% (95% confidence interval, 48% to 71%). Upacicalcet also decreased serum fibroblast growth factor-23, bone-specific alkaline phosphatase, total type 1 procollagen-N-propeptide, and tartrate-resistant acid phosphatase-5b concentrations. Adverse events were reported in 85% (88/103) and 72% (36/50) participants in the upacicalcet and placebo groups, respectively. The incidence of upper gastrointestinal adverse events, such as nausea and vomiting, was similar between the two groups. Serum corrected calcium concentrations <7.5 mg/dl were observed in 2% of participants in the upacicalcet group and no participants in the placebo group. CONCLUSIONS: Upacicalcet, a novel injectable calcimimetic, is effective and safe for secondary hyperparathyroidism patients receiving HD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Phase 3 Study of SK-1403, NCT03801980 .
引用
- Shigematsu T, Koiwa F, Isaka Y, et al. Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial. Clin J Am Soc Nephrol. 2023. PMID: 37696667. doi:10.2215/CJN.0000000000000253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。